Significance of CYP2D6 oxidation genotype as a risk factor in development of allergic diseases;Znaczenie genotypu oksydacji CYP2D6 jako czynnika zwiȩkszaja̧cego ryzyko wysta̧pienia chorób alergicznych

Polskie Archiwum Medycyny Wewnetrznej

Volumn 109, Issue 2, 2003, Pages 137-142

  Niewiński, Przemysław ^a   Orzechowska Juzwenko, Krystyna ^a   Patkowski, Janusz ^b   Mȩdrala, Wojciech ^b   Wolańczyk Mȩdrala, Anna ^b   Hurkacz, Magdalena ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b NONE

Author keywords

Allergic diseases; Allergic rhinitis; Atopic asthma; CYP2D6

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CYTOCHROME P450 2D6; DNA; FENOTEROL; GLUCOCORTICOID; SALMETEROL;

ADOLESCENT; ADULT; AGED; ALLELE; ALLERGIC ASTHMA; ALLERGIC DISEASE; ALLERGIC RHINITIS; ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; FEMALE; FORCED EXPIRATORY VOLUME; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; OXIDATION; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR;

EID: 0037237524     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Duffy D.L., Mitchell C.A., Martin N.G.: Genetic and environmental risk factors for asthma: cotwin-control study. Am. J. Respir. Crit. Care Med., 1998, 157, 840.
2. Marsh D.: Approaches toward the genetic analysis of complex traits: asthma and atopy. Am. J. Respir. Crit. Care Med., 1997, 156, 133.
3. Ricci M., Matucci A.: Source of IL-4 able to induced the development of Th2- like cells. Clin. Exp. Allergy, 1997, 27, 488.
4. Orzechowska-Juzwenko K., Milejski P, Patkowski J. i wsp.: Acetylator phenotype in patients with allergic diseases and its clinical significance. Intern. J. Clin. Pharmacol. Ther. Toxicol., 1990, 28, 420.
5. Niewiński P, Orzechowska-Juzwenko K., Patkowski J. i wsp.: Fenotyp oksydacji jako czynnik zwiȩkszaja̧cy ryzyko wysta̧pienia chorób alergicznych. Pol. Arch. Med. Wew., 1999, 101, 23.
6. Patkowski J., Orzechowska-Juzwenko K., Milejski P. i wsp.: Fenotyp acetylacji w chorobach alergicznych i w nadwrażliwości na leki. Pol. Tyg. Lek., 1992, 47, 845.
7. Nebert D. W: Polymorphisms in drug-metabolizing enzymes: what is their clinical relevance and why do they exist? Am. J. Hum. Genet., 1997, 60, 265.
8. Cavanah D.K., Cesale T.B.: Histamine. [w:] The mast cell in health and disease. Kaliner M. A., Metcalfe D. D. (red.), 1993, 321.
9. Abe Y., Ogino S., Irifune N. i wsp.: Histamine content synthesis and degradation in human nasal mucose. Clin. Exp. Allergy, 1993, 23, 132.
10. Emanuel M.B.: Histamine and the anti-histamines: a history of their discoveries. Clin. Exp. Allergy, 1999, 29, (suppl. 3, 1).
11. Murphy R.C., Wheelan P: Metabolism of leukotriens in vitro and in vivo in SRS-A to leukotriens. In the Dawning of New Treatment, edited by Holgate S., Dahlen S.E., Zeneca Blackwell Science London 1996, 101.
12. Smith C., Gough A., Leigh P, Summers B., Harding A.: Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinsons disease. Lancet, 1992, 339, 1375.
13. Niewiński P, Orzechowska-Juzwenko K.: Znaczenie genetycznie uwarunkowanego utleniania leków i ksenobiotyków w patogenezie chorób nowotworowych. Pol. Merkuriusz Lek., 1997, 9, 231.
14. Nebert D.W.: Drug-metabolizing enzymes, polymorphisms and interindividual response to environmental toxicants. Clin. Chem. Lab. Med., 2000, 38, 857.